Page last updated: 2024-12-08

2-deoxyribose 5-phosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID45934311
CHEBI ID190741
SCHEMBL ID20597055
MeSH IDM0162522

Synonyms (17)

Synonym
DEOXY-RIBOSE-5P ,
2-deoxyribose 5-phosphate
2-deoxy-alpha-d-ribose 5-phosphate
deoxyribose 5-phosphate
[(2r,3s,5r)-3,5-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
CHEBI:190741
{[(2r,3s,5r)-3,5-dihydroxyoxolan-2-yl]methoxy}phosphonic acid
2-deoxy-d-ribose-5-phosphate
deoxyribose-5-p
2-deoxyribose-5-p
2-deoxyribose-5-phosphate
2-deoxy-alpha-delta-ribose 5-phosphate
abasic deoxyribose
2'-deoxy-ribofuranose-5'-monophosphate
2-deoxy-5-o-phosphono-beta-d-erythro-pentofuranose
SCHEMBL20597055
Q27457178
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phospho sugarAny monosaccharide containing an alcoholic hydroxy group esterified with phosphoric acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (5)

PathwayProteinsCompounds
Pentose Phosphate Pathway1527
Glucose-6-phosphate Dehydrogenase Deficiency1527
Ribose-5-phosphate Isomerase Deficiency1527
Transaldolase Deficiency1527
Purine Deoxyribonucleosides Degradation414

Research

Studies (41)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (12.20)18.7374
1990's7 (17.07)18.2507
2000's19 (46.34)29.6817
2010's10 (24.39)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (7.32%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other38 (92.68%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]